Groundbreaking AI models generate novel antibiotics NG1 and DN1 that effectively combat multidrug-resistant superbugs like gonorrhea and MRSA, iteratively building and optimizing molecular structures for potency and safety.
AI startup Isomorphic Labs, spun out of DeepMind, prepares for human trials of drugs designed by cutting-edge AI paired with pharma experts, aiming for 100% conviction drugs will work before trials, promising faster, cheaper and more accurate medicine design.
AI's ability to rapidly analyze massive datasets is revolutionizing drug discovery, cutting research timelines from around 6 years to as little as 2-4 years, leading to significant cost savings and faster delivery of life-saving treatments, as evidenced by the accelerated development of COVID-19 mRNA vaccines.
OpenAI is in discussions with the FDA to explore leveraging AI, potentially through a project called cderGPT, to accelerate the drug approval process, with the FDA commissioner confirming the agency's first AI-assisted scientific review of a product.
Researchers developed a machine-learning model that can predict the transition states of chemical reactions in under a second with high accuracy, enabling efficient design of useful compounds like fuels and drugs by rapidly exploring potential reaction pathways.
Tempus AI unveils groundbreaking $200M deals with AstraZeneca and Pathos AI to build the largest AI model in oncology, harnessing multimodal data to drive biological insights, drug target discovery, and therapeutic development for cancer patients.
Researchers developed a multimodal AI tool that combines language models and graph-based models to efficiently design new molecules with desired properties from natural language queries, outperforming existing methods and potentially automating the entire molecule design and synthesis process.
Google-backed AI drug discovery startup Isomorphic Labs secured a staggering $600 million in funding led by Thrive Capital, fueling its AI engine's development and advancing partnerships with pharmaceutical giants like Eli Lilly and Novartis worth billions to revolutionize drug design.
Alphabet's AI drug discovery subsidiary Isomorphic Labs secures $600 million funding from Thrive Capital to accelerate development of its AI-powered drug design platform and advance its drug candidates into clinical trials, leveraging technology like DeepMind's AlphaFold.
TxAgent, an AI agent leveraging multi-step reasoning and real-time biomedical knowledge retrieval, revolutionizes personalized drug treatment with 92.1% accuracy, outperforming leading models and ensuring treatment recommendations align with clinical guidelines to reduce adverse events.